Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Advanced Heart Failure and Transplant
For patients acutely decompensated with ACC Stage C-D, NYHA 3-4, probable INTERMACS 4, how do you decide between MCS devices like CCM Barostim or potentially LVAD?
What are hemodynamic indices that would sway you between MCS or foregoing it?
Related Questions
Do you recommend initiating treatment with an SGLT2 inhibitor or semaglutide first for a patient with obesity and heart failure with preserved ejection fraction?
How do you use NT-proBNP in patients with chronic kidney disease or end-stage kidney disease, given that these conditions can affect NT-proBNP levels?
How do you consider and approach transition to hospice in a patient with HFrEF who does not appear to tolerate GDMT?
Should an ischemic evaluation be considered in the diagnostic work-up for new-onset diastolic heart failure/HFpEF in patients without clear anginal symptoms?
How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?
How do you think about using contraction alkalosis as a mark of achieving goal diuresis?
How do you use IVC caliber and collapsibility to guide decisions about diuresis?
How do you weigh the benefit of urinary catheter placement for strict I/O measurement with the risk of avoidable CAUTI?
Is it reasonable to start de-escalating GDMT for patients with recovered LVEF following PCI for anterior STEMI, and if so, what class of medication would you consider stopping first?
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?